Telix Pharmaceuticals Ltd (TLX) stock

TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30

$9.23−0.13 (-1.39%)

Close on Nov 13, 2026Market cap $3.13BP/E –Yield –

Telix Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $171.25M, up 33.9% from the year before.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$171.25M	+33.9%
FY2024	Dec 31, 2024	$127.93M	+50.0%
FY2023	Dec 31, 2023	$85.32M	–

Parsed from the XBRL in Telix Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TLX.

Revenue growth55.6% · median -4.3%

Operating margin3.7% · median -64.0%

Net margin-0.9% · median -51.7%

Advertisement
300 × 250

See a number that looks wrong?